INCHEON, South Korea - eTradeWire -- Eone-Diagnomics Genome Center (EDGC), a leading global genomics and precision medicine company headquartered in South Korea, is proud to announce that it has received official approval for the Clinical and Public Health Laboratory License from the California Department of Public Health (CDPH). This significant milestone enables EDGC's Incheon-based laboratory to legally accept and process clinical diagnostic samples from California and throughout the United States, under one of the most rigorous state-level regulatory frameworks in the country.

California is recognized for setting the highest standards for clinical laboratory operations in the U.S., and this approval reflects EDGC's ongoing commitment to excellence in laboratory medicine, regulatory compliance, and global clinical testing standards. With this license, EDGC becomes one of the few non-U.S. laboratories authorized to directly receive and test clinical samples from California, a state known for its stringent oversight in laboratory diagnostics.

More on eTradeWire News

• Project Home Draws Up a Blueprint for Hope on Documentary Showcase
• Real Estate Powerhouse DeLisa Rose to Speak at NAREB TX State Conference in Galveston, TX
• TEAM HUSSLE: The Unstoppable Duo Redefining the Sound of the Streets
• Premier Mobile Health Services receives $190,000 Resiliency Grant
• Celestix Launches InstaSafe Zero Trust on Microsoft Azure Marketplace

"This license is not just a regulatory achievement—it's a validation of EDGC's quality, integrity, and leadership in global genomics," said Dr. Min Seob Lee, Founder and CEO of EDGC. "We are honored to serve physicians and patients in California and across the U.S., delivering advanced clinical testing in genomics and precision medicine."

EDGC currently provides CLIA-certified and CAP-accredited testing services to over 30 countries worldwide, offering a broad portfolio of high-precision diagnostics including:

• Non-Invasive Prenatal Testing (NIPT)
• Newborn Genetic Screening
• Oncology Liquid Biopsy
• EpiClock™ Biological Age and Longevity Testing
• Disease Risk Assessment
• Comprehensive Genetic Screening Panels

This California license enhances EDGC's ability to partner with U.S. hospitals, biotech firms, and research institutions, and accelerates its mission to make personalized genomic medicine accessible on a global scale.

More on eTradeWire News

• Winners Announced for 2025 AMA Chicago Palmer Marketing Awards
• New Novel "Web Of The Angel" Is Published By Patrick Meservier
• Driving Change: Hoffman Homes Wraps Up Successful Annual Golf Outing
• A Living Legacy – New Short Film Honors George Floyd, Premieres on YouTube
• Charity Ride Rolls Out Big Support for Hoffman Homes

For more information or to inquire about EDGC's clinical services in the U.S. and internationally, please visit www.edgc.com.

About EDGC
Eone-Diagnomics Genome Center (EDGC) is a global leader in genomics and precision diagnostics, offering next-generation sequencing, bioinformatics, and AI-integrated testing platforms. With headquarters in Incheon, South Korea and global partnerships across Asia, Europe, and the U.S., EDGC is at the forefront of the DNA-driven revolution in healthcare.